Largest biotech companies in the United States by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Amgen leads the 17 biotech companies in the United States ranked by revenue, at CHF 30.9B, ahead of Gilead Sciences (CHF 24.7B) and Biogen (CHF 8.3B). Figures as of 20 Nov 2026, 18:50 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 17
- First
- AmgenCHF 30.9B
- Median
- CHF 620.2M
- Combined market value
- CHF 615B
- Countries
- 1
- Not ranked
- 3no revenue on file
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CHF 30.9B | CHF 199.1B | CHF 367.99 | 0.40% up | 30% up | ||
| 2 | Gilead SciencesGILD · Health Care | CHF 24.7B | CHF 175.2B | CHF 141.27 | 0.98% up | 31% up | ||
| 3 | BiogenBIIB · Health Care | CHF 8.3B | CHF 31B | CHF 209.49 | 0.91% up | 41% up | ||
| 4 | Neurocrine BiosciencesNBIX · Health Care | CHF 2.4B | CHF 13B | CHF 128.51 | 2.31% down | 10% up | ||
| 5 | ExelixisEXEL · Health Care | CHF 1.9B | CHF 13.4B | CHF 54.94 | 0.66% down | 55% up | ||
| 6 | ModernaMRNA · Health Care | CHF 1.6B | CHF 66B | CHF 163.13 | 2.58% down | 740% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | CHF 1.2B | CHF 8.9B | CHF 77.80 | 0.46% down | 32% up | ||
| 8 | Bio-TechneTECH · Health Care | CHF 1B | CHF 9.6B | CHF 61.08 | 0.01% up | 18% up | ||
| 9 | RepligenRGEN · Health Care | CHF 620.2M | CHF 8.9B | CHF 138.92 | 2.89% down | 5% up | ||
| 10 | Krystal BiotechKRYS · Health Care | CHF 326.9M | CHF 7.8B | CHF 262.53 | 1.05% down | 49% up | ||
| 11 | Twist BioscienceTWST · Health Care | CHF 316.4M | CHF 6B | CHF 87.45 | 6.74% down | 291% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | CHF 232.7M | CHF 3.8B | CHF 23.39 | 0.75% down | 51% up | ||
| 13 | ImmunityBioIBRX · Health Care | CHF 95.2M | CHF 5.4B | CHF 5.07 | 8.07% down | 216% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | CHF 32.9M | CHF 8.2B | CHF 96.44 | 3.85% down | 81% up | ||
| 15 | CG OncologyCGON · Health Care | CHF 3.4M | CHF 6.1B | CHF 67.85 | 1.38% down | 93% up | ||
| 16 | Revolution MedicinesRVMD · Health Care | CHF 0 | CHF 29.4B | CHF 135.70 | 1.32% up | 125% up | ||
| 17 | Scholar Rock HoldingSRRK · Health Care | CHF 0 | CHF 5B | CHF 41.27 | 2.46% down | 25% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8401 CHF). 3 companies have no revenue on file and are not ranked here.
Questions and answers
Which biotech companies in the United States rank first by revenue?
Amgen (CHF 30.9B), Gilead Sciences (CHF 24.7B) and Biogen (CHF 8.3B) are the top three of the 17 biotech companies in the United States ranked by revenue as of 20 Nov 2026, 18:50 UTC.
How many biotech companies in the United States are in this ranking?
17 are ranked by revenue. 3 more have no revenue on file and are left out rather than ranked at zero.
What are these biotech companies in the United States worth together?
The 17 biotech companies in the United States ranked by revenue have a combined market value of CHF 615B as of 20 Nov 2026, 18:50 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech companies in the United States by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.